Tasly Pharmaceutical Subsidiary Gets Drug Registration for Muscle Spasms Drug

MT NewswiresDec 5 12:04

Tasly Pharmaceutical Group (600535.SH): Subsidiary obtained the pharmaceutical registration certificate.

On December 4th, Gelonghui reported that Tasly Pharmaceutical Group (600535.SH) announced that its wholly-owned subsidiary, Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (hereinafter referred to as "Jiangsu Diyi"), received the pharmaceutical registration certificate for Baclofen Oral Solution approved by the National Medical Products Administration. According to the product instructions, Baclofen Oral Solution is indicated for severe but reversible muscle spasms caused by multiple sclerosis, and may be effective for spasms caused by infectious, degenerative, traumatic, tumor, or unknown causes of spinal cord diseases.

Gelonghui FinanceDec 4 15:37

Express News | Tasly Pharmaceutical Group: Subsidiary Barufen Oral Solution First Approved

BreakingsDec 4 15:33

Tasly Pharmaceutical Group (600535.SH) announced equity distribution for the third quarter of 2024: a dividend of 0.07 yuan per share, with stock registration on December 5th.

Tasly Pharmaceutical Group (600535.SH) has announced the equity distribution notice for the third quarter of 2024, and this profit distribution is based on the plan...

Zhitong FinanceNov 29 16:24

Tasly Pharmaceutical Group (600535): Core varieties under short-term pressure, China Resources Sanjiu Medical & Pharmaceutical empowerment is expected.

Event description: The company released its third quarter report for 2024, with short-term performance under pressure: In the first three quarters of 2024, the revenue was approximately 6.463 billion yuan, a year-on-year decrease of 1.66%. The traditional chinese medicine industry grew by 2.18% year-on-year, and pharmaceutical commerce.

Yongxing SecuritiesNov 29 00:00

Tasly Pharmaceutical Group: Some products price reduction led to a decline in Q3 gross margin. All parties are actively promoting the trade with China Resources Sanjiu Medical & Pharmaceutical | Focus on earnings conference

① Affected by the overall low prosperity of the pharmacy industry, the company's pharmaceutical commerce sector saw a decline in revenue in the third quarter this year; the pharmaceutical industry sector's revenue grew year-on-year, but price reductions on some products led to a decrease in gross margin, and the company expects the gross margin to remain stable in the future. ② Regarding the equity trade matters between the company's major shareholder and china resources sanjiu medical & pharmaceutical, the company's general manager Cai Jinyong stated that the company and relevant parties are actively promoting various works for this transaction.

cls.cnNov 27 22:29